Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Accuray ( (ARAY) ) has issued an announcement.
On October 18, 2025, Accuray entered into a consulting agreement with Dedication Capital, appointing Steven F. Mayer as Transformation Board Sponsor to lead strategic initiatives, with compensation including a base fee and equity awards. Additionally, on October 20, 2025, Accuray announced the appointment of Steve La Neve as CEO, succeeding Suzanne Winter, as part of a broader transformation plan aimed at enhancing competitiveness and achieving sustainable growth.
The most recent analyst rating on (ARAY) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Accuray stock, see the ARAY Stock Forecast page.
Spark’s Take on ARAY Stock
According to Spark, TipRanks’ AI Analyst, ARAY is a Neutral.
Accuray’s overall stock score reflects significant financial challenges, including declining revenue and high leverage, which are major concerns. While technical indicators show some positive momentum, the valuation is weak due to negative earnings. The earnings call offered mixed insights, with some growth in service revenue but offset by geopolitical risks and regional revenue declines.
To see Spark’s full report on ARAY stock, click here.
More about Accuray
Accuray is a company dedicated to expanding the potential of radiation therapy to improve lives by delivering innovative solutions for complex and common cases in oncology and neuro-radiosurgery. Headquartered in Madison, Wisconsin, Accuray is committed to continuous innovation and partners with clinicians and administrators worldwide.
Average Trading Volume: 831,085
Technical Sentiment Signal: Sell
Current Market Cap: $190.5M
For detailed information about ARAY stock, go to TipRanks’ Stock Analysis page.